關於本有聲書
Renal anemia is a common and significant complication of chronic kidney disease (CKD), affecting millions of individuals worldwide. It is characterized by a reduction in red blood cell count and hemoglobin levels, primarily due to the kidneys' decreased ability to produce erythropoietin (EPO), a hormone critical for red blood cell production in the bone marrow. As kidney function declines, the synthesis of EPO diminishes, leading to insufficient stimulation of erythropoiesis and, consequently, anemia.
The classification of renal anemia falls under the broader category of normocytic, normochromic anemia, indicating that the red blood cells are typically of normal size and hemoglobin content, but their numbers are reduced. This type of anemia often develops insidiously and becomes more pronounced as CKD progresses from stage 3 to stages 4 and 5. In end-stage renal disease (ESRD), renal anemia becomes nearly universal among patients, necessitating targeted intervention and long-term management.
Epidemiologically, renal anemia is prevalent in over 90% of patients undergoing dialysis and affects a significant portion of individuals with moderate to severe CKD who are not yet on dialysis. It contributes to a variety of adverse clinical outcomes, including reduced exercise capacity, cognitive impairment, left ventricular hypertrophy, and increased mortality. The burden of renal anemia also extends beyond clinical complications, with patients often reporting debilitating fatigue, decreased productivity, and a diminished quality of life.
